GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of how much of what we believe about endpoint actually comes from SURMOUNT threads — 52 comments in the full submission. View in context.
1.8k
c/trialwatch·submitted 5 months ago by u/joaquin_stanescu

how much of what we believe about endpoint actually comes from SURMOUNT threads

Trial Databranch of 7 comments

Asking properly rather than in a comment on somebody else’s thread: how much of what we believe about endpoint actually comes from SURMOUNT threads. Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact every fortnight. The discontinuation numbers were the most…

Read the full submission and all 52 comments →

This branch

7 comments, started 5 months ago
u/rina_sobczak35 points·5 months ago

Read a press release and the publication three months apart. The hedging in the second one was substantial.

replysharereportpermalink
u/annika_fonseca29 points·5 months ago

phase 2 finds a dose, phase 3 measures the effect

replysharereportpermalink
u/curious_panel_only20 points·5 months ago·edited

That is the 68-week readout, not the 72-week one. Different trial, different duration.

replysharereportpermalink
u/hugo_bergstrom9 points·5 months ago

a mean is not a promise

replysharereportpermalink
u/joaquin_stanescuOP7 points·5 months ago

Started keeping the trial identifiers straight in a note file because I kept mixing up two programmes in the same sentence.

replysharereportpermalink
u/ewan_tulloch10 points·5 months ago

check who the comparator was before you compare anything

replysharereportpermalink
u/receipts_or_nothingvetting5 points·5 months ago

Quoted a figure here confidently, got asked whether it was ITT, went and checked, and it was not. Learned something.

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →